First candidate from Tenvie’s product engine to enter clinical developmentPhase 1 first-in-human study to evaluate single and multiple ascending ...
HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments ...
Results show 83% sensitivity and 89% specificity in predicting whether small molecule drugs will cause clinical seizures CNS-3D Brain Organoids are 13x more predictive than animal models Data from 120 ...
Gossamer Bio has disclosed that it has halted development of GB5121 and terminated all clinical studies of the drug following a partial clinical hold imposed by the FDA after two patients died in a ...
AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotechnology mergers and acquisitions (M&As) are increasingly shaped by a clear strategic evolution. Pharmaceutical ...
SAN FRANCISCO, April 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients ...
Central Nervous System (CNS) therapies have significantly progressed in the last decade, propelled by emerging treatment modalities including gene therapies. Neurological indications remain amongst ...
LAS VEGAS, March 6, 2026 /PRNewswire/ -- The International Society for CNS Drug Development (ISCDD), a non-profit organization dedicated to advancing central nervous system drug development, is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results